APREA THERAPEUTICS INC (APRE) Stock Price & Overview
NASDAQ:APRE • US03836J2015
Current stock price
The current stock price of APRE is 0.6992 USD. Today APRE is down by -2.26%. In the past month the price decreased by -22.33%. In the past year, price decreased by -54.89%.
APRE Key Statistics
- Market Cap
- 4.887M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.38
- Dividend Yield
- N/A
APRE Stock Performance
APRE Stock Chart
APRE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to APRE. When comparing the yearly performance of all stocks, APRE is a bad performer in the overall market: 92.72% of all stocks are doing better.
APRE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to APRE. APRE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
APRE Earnings
On March 16, 2026 APRE reported an EPS of -0.32 and a revenue of 3.34K. The company beat EPS expectations (19.56% surprise).
APRE Forecast & Estimates
9 analysts have analysed APRE and the average price target is 5.44 USD. This implies a price increase of 678.03% is expected in the next year compared to the current price of 0.6992.
For the next year, analysts expect an EPS growth of 14.71% and a revenue growth -78.07% for APRE
APRE Groups
Sector & Classification
APRE Financial Highlights
Over the last trailing twelve months APRE reported a non-GAAP Earnings per Share(EPS) of -2.38. The EPS increased by 40.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.08% | ||
| ROE | -95.68% | ||
| Debt/Equity | 0 |
APRE Ownership
APRE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.93 | 365.463B | ||
| AMGN | AMGEN INC | 15.01 | 184.669B | ||
| GILD | GILEAD SCIENCES INC | 15.85 | 173.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 110.325B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.32 | 80.669B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.27 | 43.81B | ||
| INSM | INSMED INC | N/A | 35.309B | ||
| NTRA | NATERA INC | N/A | 29.036B | ||
| BIIB | BIOGEN INC | 10.72 | 25.293B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.74 | 24.53B | ||
| MRNA | MODERNA INC | N/A | 19.261B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.898B | ||
| INCY | INCYTE CORP | 12.39 | 18.878B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About APRE
Company Profile
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. The company is headquartered in Doylestown, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2019-10-03. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. The company is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. The company also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
Company Info
IPO: 2019-10-03
APREA THERAPEUTICS INC
3805 Old Easton Road
Doylestown PENNSYLVANIA 02116 US
CEO: Christian S. Schade
Employees: 8
Phone: 12159484119
APREA THERAPEUTICS INC / APRE FAQ
Can you describe the business of APREA THERAPEUTICS INC?
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. The company is headquartered in Doylestown, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2019-10-03. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. The company is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. The company also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
What is the current price of APRE stock?
The current stock price of APRE is 0.6992 USD. The price decreased by -2.26% in the last trading session.
What is the dividend status of APREA THERAPEUTICS INC?
APRE does not pay a dividend.
What is the ChartMill technical and fundamental rating of APRE stock?
APRE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for APRE stock?
The Revenue of APREA THERAPEUTICS INC (APRE) is expected to decline by -78.07% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
When does APREA THERAPEUTICS INC (APRE) report earnings?
APREA THERAPEUTICS INC (APRE) will report earnings on 2026-05-12.
What is the Short Interest ratio of APREA THERAPEUTICS INC (APRE) stock?
The outstanding short interest for APREA THERAPEUTICS INC (APRE) is 2% of its float.